美国 · SEC FORM 4
LENZ Therapeutics, Inc.
LENZ · Nasdaq · CIK 0001815776 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-03-27 · George Jeffrey P..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 10,560,869
- 上期报告
- 10,629,972
- 日均成交量
- 766,161
- 回补天数
- 13.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-27 | Schimmelpennink Evert B. | 买入 (P) | Common Stock | 28,089 | USD 8.95 | USD 251,397 | SEC 申报 ↗ |
| 2026-03-27 | George Jeffrey P. | 买入 (P) | Common Stock | 5,592 | USD 8.92 | USD 49,881 | SEC 申报 ↗ |
| 2026-03-27 | Chevallard Daniel R. | 买入 (P) | Common Stock | 7,500 | USD 8.57 | USD 64,275 | SEC 申报 ↗ |
| 2025-11-07 | MCCOLLUM JAMES W | 买入 (P) | Common Stock | 10,500 | USD 22.79 | USD 239,295 | SEC 申报 ↗ |
| 2025-11-07 | Chevallard Daniel R. | 买入 (P) | Common Stock | 2,198 | USD 22.76 | USD 50,025 | SEC 申报 ↗ |
| 2024-05-14 | Chevallard Daniel R. | 买入 (P) | Common Stock | 3,188 | USD 15.68 | USD 49,988 | SEC 申报 ↗ |
| 2024-05-13 | MCCOLLUM JAMES W | 买入 (P) | Common Stock | 31,332 | USD 15.99 | USD 500,999 | SEC 申报 ↗ |
| 2024-03-21 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stockj | 64,971 | USD 15.03 | USD 976,514 | SEC 申报 ↗ |
| 2024-03-21 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 933,038 | USD 15.03 | USD 14,023,561 | SEC 申报 ↗ |
| 2022-04-12 | AKKARAJU SRINIVAS; Samsara BioCapital, L.P. | 买入 (P) | Common Stock | 350,000 | USD 4.08 | USD 1,428,000 | SEC 申报 ↗ |
| 2022-04-11 | Gutry Phil | 买入 (P) | Common Stock | 5,000 | USD 4.01 | USD 20,050 | SEC 申报 ↗ |
| 2022-04-11 | AKKARAJU SRINIVAS; Samsara BioCapital, L.P. | 买入 (P) | Common Stock | 74,464 | USD 4.07 | USD 303,068 | SEC 申报 ↗ |
| 2022-01-24 | AKKARAJU SRINIVAS; Samsara BioCapital, L.P. | 买入 (P) | Common Stock | 23,000 | USD 8.70 | USD 200,100 | SEC 申报 ↗ |
| 2022-01-21 | AKKARAJU SRINIVAS; Samsara BioCapital, L.P. | 买入 (P) | Common Stock | 100,000 | USD 8.99 | USD 899,000 | SEC 申报 ↗ |
| 2022-01-20 | AKKARAJU SRINIVAS; Samsara BioCapital, L.P. | 买入 (P) | Common Stock | 43,105 | USD 8.92 | USD 384,497 | SEC 申报 ↗ |
Form 4 申报证据
9 transaction lines in the latest 365-day window; 95 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-27 | Schimmelpennink Evert B. | 买入 (P) | Common Stock | 28,089 | USD 8.95 | USD 251,397 | SEC 申报 ↗ |
| 2026-03-27 | George Jeffrey P. | 买入 (P) | Common Stock | 5,592 | USD 8.92 | USD 49,881 | SEC 申报 ↗ |
| 2026-03-27 | Chevallard Daniel R. | 买入 (P) | Common Stock | 7,500 | USD 8.57 | USD 64,275 | SEC 申报 ↗ |
展开近期 Form 4 证据 (7 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-27 | Schimmelpennink Evert B. | 买入 (P) | Common Stock | 28,089 | USD 8.95 | USD 251,397 | SEC 申报 ↗ |
| 2026-03-27 | George Jeffrey P. | 买入 (P) | Common Stock | 5,592 | USD 8.92 | USD 49,881 | SEC 申报 ↗ |
| 2026-03-27 | Chevallard Daniel R. | 买入 (P) | Common Stock | 7,500 | USD 8.57 | USD 64,275 | SEC 申报 ↗ |
| 2025-11-17 | Olsson Shawn | 卖出 (S) | Common Stock | 10,000 | USD 26.10 | USD 261,046 | SEC 申报 ↗ |
| 2025-11-17 | Olsson Shawn | 期权行权／转换 (M) | Common Stock | 10,000 | USD 2.08 | USD 20,800 | SEC 申报 ↗ |
| 2025-11-07 | MCCOLLUM JAMES W | 买入 (P) | Common Stock | 10,500 | USD 22.79 | USD 239,295 | SEC 申报 ↗ |
| 2025-11-07 | Chevallard Daniel R. | 买入 (P) | Common Stock | 2,198 | USD 22.76 | USD 50,025 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | LENZ |
| CIK | 0001815776 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 95 transaction lines from 2021-01-14 to 2026-03-27 30 P purchase lines · 36 S sale lines · 29 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.